MX368868B - Composiciones farmacéuticas orales de dabigatrán etexilato. - Google Patents

Composiciones farmacéuticas orales de dabigatrán etexilato.

Info

Publication number
MX368868B
MX368868B MX2014010040A MX2014010040A MX368868B MX 368868 B MX368868 B MX 368868B MX 2014010040 A MX2014010040 A MX 2014010040A MX 2014010040 A MX2014010040 A MX 2014010040A MX 368868 B MX368868 B MX 368868B
Authority
MX
Mexico
Prior art keywords
compositions
dabigatran etexilate
pharmaceutical compositions
pharmaceutically acceptable
oral pharmaceutical
Prior art date
Application number
MX2014010040A
Other languages
English (en)
Other versions
MX2014010040A (es
Inventor
S Pilgaonkar Pratibha
T Rustomjee Maharukh
S Gandhi Anilkumar
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47739283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX368868(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of MX2014010040A publication Critical patent/MX2014010040A/es
Publication of MX368868B publication Critical patent/MX368868B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones que comprenden una mezcla de al menos dos tipos de partículas en las que a) el primer tipo de partículas comprenden dabigatrán etexilato en forma de la base libre o en forma de sales, polimorfos, solvatos o hidratos farmacéuticamente aceptables del mismo; y b) el segundo tipo de partículas comprende al menos un ácido orgánico farmacéuticamente aceptable, uso de dichas composiciones en la reducción del riesgo de desarrollar accidente cerebrovascular y embolia sistémica en pacientes con fibrilación auricular no valvular y/o en la prevención de acontecimientos tromboembólicos venosos en pacientes adultos que se han sometido a cirugía de artroplastia total de rodilla o cirugía de artroplastia total de cadera programada y procedimientos para la preparación de dichas composiciones.
MX2014010040A 2012-02-21 2013-02-21 Composiciones farmacéuticas orales de dabigatrán etexilato. MX368868B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN461MU2012 2012-02-21
PCT/EP2013/053426 WO2013124340A1 (en) 2012-02-21 2013-02-21 Oral pharmaceutical compositions of dabigatran etexilate

Publications (2)

Publication Number Publication Date
MX2014010040A MX2014010040A (es) 2014-11-10
MX368868B true MX368868B (es) 2019-10-11

Family

ID=47739283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010040A MX368868B (es) 2012-02-21 2013-02-21 Composiciones farmacéuticas orales de dabigatrán etexilato.

Country Status (27)

Country Link
US (3) US11013729B2 (es)
EP (2) EP2817000B1 (es)
JP (1) JP6215239B2 (es)
KR (1) KR102090242B1 (es)
CN (2) CN110123774A (es)
AU (1) AU2013224146B2 (es)
BR (1) BR112014020474B1 (es)
CA (1) CA2864423C (es)
CY (1) CY1124678T1 (es)
DK (1) DK2817000T3 (es)
ES (1) ES2895918T3 (es)
HR (1) HRP20211606T1 (es)
HU (1) HUE056194T2 (es)
IL (1) IL234032B (es)
IN (1) IN2014DN06734A (es)
JO (1) JO3616B1 (es)
LT (1) LT2817000T (es)
MX (1) MX368868B (es)
NZ (1) NZ628301A (es)
PL (1) PL2817000T3 (es)
PT (1) PT2817000T (es)
RS (1) RS62566B1 (es)
RU (1) RU2633482C2 (es)
SI (1) SI2817000T1 (es)
SM (1) SMT202100608T1 (es)
WO (1) WO2013124340A1 (es)
ZA (1) ZA201405855B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013224146B2 (en) 2012-02-21 2017-06-08 Towa Pharmaceutical Europe, S.L. Oral pharmaceutical compositions of dabigatran etexilate
CN104224754A (zh) * 2013-06-21 2014-12-24 四川海思科制药有限公司 一种达比加群酯药物组合物及其制备方法
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物
EP2853260A1 (en) * 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN104784147B (zh) * 2014-01-20 2018-01-23 成都苑东生物制药股份有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
CN104994856A (zh) * 2014-01-30 2015-10-21 杭州领业医药科技有限公司 达比加群酯及其盐的投药制剂及其制备方法
CN104922092A (zh) * 2014-03-19 2015-09-23 陕西天森药物研究开发有限公司 一种通过包裹法制备的达比加群酯或其盐和水合物的药物组合
WO2015145462A1 (en) 2014-03-26 2015-10-01 Cadila Healthcare Limited Pharmaceutical compositions of dabigatran
CN104095830A (zh) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 一种甲磺酸盐达比加群酯胶囊的制备方法
CN104825422B (zh) * 2014-09-29 2017-12-12 普济生物科技（台州）有限公司 含达比加群酯甲磺酸盐的药物组合物及其制备方法
CN105560206A (zh) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 一种达比加群酯胶囊的制备
CN105764509B (zh) * 2014-11-03 2019-03-19 杭州领业医药科技有限公司 达比加群酯或其盐的投药制剂及其制备方法
EP4205743A1 (en) 2014-12-31 2023-07-05 Shenzhen Pharmacin Co., Ltd. Pharmaceutical composition and preparation method therefor
WO2017103945A1 (en) * 2015-12-15 2017-06-22 Strides Shasun Limited Pharmaceutical compositions
CN106890148A (zh) * 2015-12-21 2017-06-27 青岛黄海制药有限责任公司 一种达比加群酯片剂及其制备
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
JP2018184375A (ja) * 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
TR201706848A2 (tr) * 2017-05-10 2018-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
WO2019004980A2 (en) * 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE
TR201722353A2 (tr) * 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatran eteksi̇lat i̇çeren oral uygulama i̇çi̇n farmasöti̇k formülasyon
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722630A2 (es) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
WO2020032885A2 (en) 2018-05-04 2020-02-13 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Capsule-in-capsule compositions of dabigatran etexilate
TR201905308A2 (tr) * 2019-04-09 2020-10-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A capsule formulation of dabigatran etexilate
CN113577067B (zh) * 2021-06-03 2023-08-15 北京福元医药股份有限公司 一种甲磺酸达比加群酯药物制剂
CN115006363A (zh) * 2022-06-23 2022-09-06 上海信谊万象药业股份有限公司 一种牡蛎碳酸钙咀嚼片及其制备方法
WO2024175037A1 (zh) * 2023-02-21 2024-08-29 广州玻思韬控释药业有限公司 达比加群酯或其药物可接受的盐的微丸

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
JPH04103525A (ja) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
KR20010012402A (ko) 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
MXPA03001958A (es) * 2000-09-06 2003-06-24 Tanabe Seiyaku Co Preparaciones para administrar oral.
JP4179784B2 (ja) * 2001-02-15 2008-11-12 田辺三菱製薬株式会社 口腔内速崩壊性錠
ES2380704T3 (es) 2002-03-07 2012-05-17 Boehringer Ingelheim International Gmbh Metanosulfonato de éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino--imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carb3onil)-piridin-2-il-amino]-propiónico
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10209985A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
CN1976903A (zh) 2004-06-02 2007-06-06 法莫西克立克斯公司 因子VⅡa抑制剂
ES2438017T3 (es) 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
CN101365453A (zh) * 2006-02-09 2009-02-11 特瓦制药工业有限公司 双嘧达莫缓释制剂及其制备方法
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
CA2716642C (en) 2008-03-28 2017-02-28 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
RU2010143901A (ru) * 2008-03-28 2012-05-10 Бёрингер Ингельхайм Интернациональ Гмбх (De) Способ получения композиций дабигатрана для перорального введения
AR072557A1 (es) 2008-07-14 2010-09-08 Boehringer Ingelheim Int Proceso para preparar composiciones de medicamentos que contienen dabigatran
US20130052262A1 (en) * 2010-03-01 2013-02-28 Sandra Brueck Dabigatran etexilate-containing oral pharmaceutical composition
EP2588090B2 (en) * 2010-07-01 2023-11-22 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
WO2012162492A1 (en) 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
AU2013224146B2 (en) 2012-02-21 2017-06-08 Towa Pharmaceutical Europe, S.L. Oral pharmaceutical compositions of dabigatran etexilate
CN102793699B (zh) * 2012-08-06 2014-06-04 严轶东 一种含有达比加群酯的药用组合物

Also Published As

Publication number Publication date
EP3858337A3 (en) 2021-09-29
US20150030680A1 (en) 2015-01-29
JO3616B1 (ar) 2020-08-27
HK1203832A1 (en) 2015-11-06
HRP20211606T1 (hr) 2022-01-21
LT2817000T (lt) 2021-11-10
DK2817000T3 (da) 2021-10-11
ZA201405855B (en) 2015-11-25
US11752142B2 (en) 2023-09-12
AU2013224146B2 (en) 2017-06-08
SI2817000T1 (sl) 2022-02-28
IL234032B (en) 2020-06-30
RU2633482C2 (ru) 2017-10-12
AU2013224146A1 (en) 2014-08-28
PL2817000T3 (pl) 2022-03-28
WO2013124340A1 (en) 2013-08-29
PT2817000T (pt) 2021-11-02
BR112014020474A2 (pt) 2020-02-11
BR112014020474B1 (pt) 2022-03-29
JP2015511241A (ja) 2015-04-16
HUE056194T2 (hu) 2022-01-28
MX2014010040A (es) 2014-11-10
CA2864423C (en) 2021-08-10
US20240139168A1 (en) 2024-05-02
EP2817000A1 (en) 2014-12-31
EP3858337A2 (en) 2021-08-04
IL234032A0 (en) 2014-09-30
RU2014138036A (ru) 2016-04-20
CN110123774A (zh) 2019-08-16
US11013729B2 (en) 2021-05-25
JP6215239B2 (ja) 2017-10-18
SMT202100608T1 (it) 2021-11-12
EP2817000B1 (en) 2021-08-04
CA2864423A1 (en) 2013-08-29
RS62566B1 (sr) 2021-12-31
KR20140135216A (ko) 2014-11-25
KR102090242B1 (ko) 2020-03-18
IN2014DN06734A (es) 2015-05-22
CY1124678T1 (el) 2022-07-22
CN104114158A (zh) 2014-10-22
ES2895918T3 (es) 2022-02-23
NZ628301A (en) 2015-07-31
US20210244719A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
MX368868B (es) Composiciones farmacéuticas orales de dabigatrán etexilato.
PH12022553251A1 (en) Methods for the administration of certain vmat2 inhibitors
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MY190835A (en) Bicyclic heterrocyclic derivatives as bromodomain inhibitors
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
PH12013502277A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
CO6640207A2 (es) Formulaciones de apixaban
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
SG10201908582TA (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
MX2015010829A (es) Compuestos terapeuticos y sus usos.
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
IN2014MU01042A (es)
WO2015116856A3 (en) Farnesoid x receptor antagonists
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
WO2013175494A3 (en) Controlled release pharmaceutical formulations of direct thrombin inhibitors
MX345656B (es) (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.
TN2015000267A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2014141035A3 (en) Fused heterocyclyl derivatives as nampt inhibitors
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
TN2014000060A1 (en) Benzothiazolone compound
HK1243704A1 (zh) 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ARLANXEO DEUTSCHLAND GMBH

FG Grant or registration